GORT

Reviews

Hidac (High-Dose Ara-C; Cytarabine; Cytosine Arabinoside

Di: Everly

A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine

Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule ...

Ara-C remains one of the most effective drugs used in the treatment of acute leukemia and other hematopoietic malignancies. In particular, high-dose ara-C is used during

HiDAC (High-Dose Ara-C; Cytarabine; Cytosine Arabinoside

The aim of this study is to determine whether the addition of mitoxantrone to high dose cytarabine improves the outcome of treatment in patients with relapsed or refractory

High-dose cytosine arabinoside or ARA-C (HDAC) has been shown to be an effective regimen in patients who are refractory to conventional doses. Neurotoxicity, a side

We report a rare case of intracranial hypertension following high dose cytosine arabinoside (HiDAC) in a 20-year-old man, with precursor B-cell acute lymphoblastic leukemia (ALL). A five

The pharmacokinetics of high-dose cytosine arabinoside (HiDAC) given as a three-hour intravenous infusion at 3 g/m2 were studied in five patients with acute leukemia during relapse

  • High-dose cytosine arabinoside-induced symptomatic bradycardia
  • Mitoxantrone and high-dose ara-C in refractory malignancies: a
  • Effects of high-dose cytarabine
  • Bilder von HiDAC High-Dose Ara-c; Cytarabine; Cytosine Arabinoside

In recent years, multiple cycles of high-dose cytarabine (HDAC) therapy (at 3.0 g/m 2 every 12 hours) have been commonly used as the consolidation therapy in multicenter trials; it was observed to maximize Ara-C’s anti-leukemia effect in

We report a rare case of intracranial hypertension following high dose cytosine arabinoside (HiDAC) in a 20-year-old man, with precursor B-cell acute lymphoblastic leukemia

Ara-C remains one of the most effective drugs used in the treatment of acute leukemia and other hematopoietic malignancies. In particular, high-dose ara-C is used during

Alteration of the pharmacokinetics of high-dose ara-C by its

All patients had daily neurologic exams including prior to each dose of HiDAC and at the beginning of each nursing shift. The primary endpoint was tolerability, defined as average dose per cycle, rate of dose reductions,

He was planned for post remission consolidation with 3 cycles of high-dose Ara-C chemotherapy (HiDAC–3 g/m 2 twice daily on alternate days for 3 days, total dose of 18 g/m 2

Ara-C remains one of the most effective drugs used in the treatment of acute leukemia and other hematopoietic malignancies. In particular, high- dose ara-C is used during remission induction

The pharmacokinetics of high-dose cytosine arabinoside (HiDAC) given as a three-hour intravenous infusion at 3 g/m2 were studied in five patients with acute leukemia during relapse

The current standard of care for induction therapy in the treatment of acute myeloid leukemia (AML) consists of a “7 + 3” regimen, which includes 7 days of cytarabine 100 to 200 mg/m 2

Cytarabine side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal

What is HiDAC? HiDAC is the abbreviation for high-dose cytarabine. Cytarabine (also called cytosine arabinidose or Ara-C) is an antimetabolite chemotherapy drug that prevents the

Cytarabine Side Effects: Common, Severe, Long Term

Ara-C is an effective chemotherapeutic agent used in acute myeloblastic leukemia (AML). High-dose Ara-C (HiDAC) regimens have been found to be effective in these refractory/relapse

Cytarabine may affect your skin. Your doctor or nurse can tell you what to expect. If your skin feels dry, try using an unperfumed moisturising cream every day. Cytarabine can cause a rash,

This pharmacologic impediment is eliminated with the blood levels attained during the infusion of gram doses (1–3 gm/m2) of the drug (high-dose ara-C, HiDaC) for shorter periods of time, a C

Real world evidence is lacking on the safety of full dose HiDAC (total 18 grams/cycle) in fit older adults in the 60-75 age range. Methods.

We report a rare case of intracranial hypertension following high dose cytosine arabinoside (HiDAC) in a 20-year-old man, with precursor B-cell acute lymphoblastic leukemia

Cytarabine is a type of chemotherapy drug called an anti metabolite . It kills cancer cells by stopping them from making and repairing DNA that they need to grow and multiply. How do

Low-dose Cytarabine for Acute Myeloid Leukaemia

The most efficient chemotherapeutic agents are anthracyclin and Ara-C. Ara-C is administered as a standard dose during induction and a high dose during consolidation. Besides bone marrow

High dose cytarabine (HIDAC) either alone or in combination with anthracyclines is active in the treatment of AML inducing remission in 50–81% of patients with previously

High-dose cytosine arabinoside (HiDAC) and intermediate-dose cytosine arabinoside (IDAC) have been introduced as effective and safe consolidation chemotherapy in

Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in

Initial dose levels were mitoxantrone 2 mg/m2 infused over 30 minutes, followed by high-dose ara-C 750 mg/m2 infused over 3 hours repeated once at 24 hours (total dose 4 mg/m2

Ara-C remains one of the most effective drugs used in the treatment of acute leukemia and other hematopoietic malignancies. In particular, high-dose ara-C is used during

Cardiac complications of high-dose cytosine arabinoside (HiDAC), although rare, predominantly include pericarditis, pericardial effusion and cardiomyopathy (with concurrent